 - COVID-19 vaccine efforts to be re-allocated to accelerate the development of second-generation program in collaboration with GSK - First-generation vaccine candidate, CVnCoV, to be withdrawn from regulatory review due to potential overlap with approval timelines for a second-generation candidate TÜBINGEN, GERMANY and BOSTON, MA ACCESSWIRE October 12, 2021 CureVac N.V. NASDAQ:CVAC, a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid mRNA, today announced the strategic decision to focus its COVID-19 vaccine development towards the development of second-generation mRNA vaccine candidates in collaboration with GSK and to withdraw its first-generation COVID-19 vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency EMA. 